Maint. Improv. of Outcomes rel. to Skin Clearance, Itch, Sleep & QoL with Baricitinib in Adults with Mod.-to-Sev. Atopic Dermatitis treated for up to 200Weeks in a Randomized Trial
Por:
Wollenberg, A, Costanzo, A, Vestergaard, C, Barbarot, S, Carrascosa, JM, Morawska, K, Vardar, B, Pandey, H, Sabatino, S, Silverberg, J and Schlöbe, A
Publicada:
1 abr 2025
Resumen:
Filiaciones:
Wollenberg, A:
Ludwig Maximillian Univ, Univ Hosp, Munich, Germany
Costanzo, A:
Univ Med Sch Dermatol, Via Alessandro Manzoni, Rozzano, Germany
Vestergaard, C:
Aarhus Univ Hosp, Aarhus, Denmark
Barbarot, S:
Univ Hosp Nantes, Nantes, France
:
Hosp Univ Germans Trias I Pujol, Barcelona, Spain
Morawska, K:
Eli Lilly & Co, Indianapolis, IN USA
Vardar, B:
Eli Lilly & Co, Indianapolis, IN USA
Pandey, H:
Eli Lilly & Co, Indianapolis, IN USA
Sabatino, S:
Eli Lilly & Co, Indianapolis, IN USA
Silverberg, J:
George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
Schlöbe, A:
Lilly Deutschland, Bad Homburg, Germany
|